Work

Computational identification of quinolinol based estrogen receptor alpha antagonists as promising therapeutics for MCF 7 breast cancer

Year: 2026
Type: article
Abstract: Breast cancer is a major cause of cancer-related death worldwide, with estrogen receptor alpha (ER-α) being an important therapeutic target for hormone-dependent MCF-7 breast cancer. This study aimed to use a computer-aided drug design (CADD) methodology to assess 22 quinolinol analogues as potential ER-α antagonists. The CADD methodology consisted of Gaussian field-based three-dimensional quantitative structure–activity relationship (3D-QSAR) analysis, pharmacophore modeling, prediction of ADMET properties, molecular docking, molecular dynamics simulation (MD), and density functional theory (DFT) calculations. 3D-QSAR model exhibited good predictive ability (R 2 = 0.9516, Q 2 = 0.5989, RMSE = 0.82, and Pearson's r = 0.845). The results of the pharmacophore analysis showed that the critical features for anticancer activity are an aromatic ring, hydrophobicity, and hydrogen bond acceptor. According to the ADMET evaluation, compounds 1, 7, 25, and 13 have the highest potential to be developed into drug-like substances, with compound 1 having best ADMET score of 6.348. Molecular docking study of the ligands with ER-α (PDB ID: 3ERT) demonstrated that ligands 7, 1 and 25 exhibited significantly better binding affinities (− 11.98, − 11.48, and − 11.04 kcal/mol, respectively) than 4-hydroxytamoxifen (− 8.26 kcal/mol). MD simulations showed that ligand 7 formed a considerably more compact and stable ER-α complex through consistent hydrogen bond interactions during 100 ns simulation. DFT analyses also indicated that ligand 7 had kinetic stability and significantly better electronic properties than the other ligands studied suggesting it for the development of breast cancer drugs that can target ER-α.
Language: English
Subfield: Drug Discovery
Open Access status: diamond
OpenAlex ID: W7165584140
FWCI:
Cites: 33
Cited by:
Related to: 10